anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The evidence for the efficacy of DATSCAN in visualizing striatal dopamine transporters in adult patients with DLB is derived from the scientific literature. In 55 patients clinically diagnosed with DLB or with Alzheimer's disease, the results of consensus blinded visual assessment of the DATSCAN images were compared to neuropathological diagnosis made using standard international criteria at autopsy. The patients were 38% female and of ages 63 to 95 years (mean 77 years) at the time of DATSCAN imaging. The median administered DATSCAN activity was 150 MBq to 185 MBq (4.1 mCi to 4.9 mCi). DATSCAN images were rated as normal or abnormal [see Dosage and Administration (2.7)]. Based on autopsy diagnosis, the sensitivity and specificity of DATSCAN for DLB was 80% (95% CI 61% to 92%) and 92% (95% CI 74% to 99%), respectively. 

The effectiveness of DATSCAN as a screening or confirmatory test and for monitoring disease progression or response to therapy has not been established.
VIVITROL must be prepared and administered by a healthcare provider. 

VIVITROL must ONLY be administered as a deep intramuscular gluteal injection.

VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising, or pruritus; however, in some cases injection site reactions may be very severe. In the clinical trials, one patient developed an area of induration that continued to enlarge after 4 weeks, with subsequent development of necrotic tissue that required surgical excision. In the postmarketing period, additional cases of injection site reaction with features including induration, cellulitis, hematoma, abscess, sterile abscess, and necrosis, have been reported. Some cases required surgical intervention, including debridement of necrotic tissue. Some cases resulted in significant scarring. The reported cases occurred primarily in female patients. 

VIVITROL is administered as a deep intramuscular gluteal injection, and inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions. The needles provided in the carton are customized needles. VIVITROL must not be injected using any other needle. The needle lengths (either 1 1/2 or 2 inches) may not be adequate in every patient because of body habitus. Body habitus should be assessed prior to each injection for each patient to assure that the proper needle is selected and that the needle length is adequate for intramuscular administration. For patients with a larger amount of subcutaneous tissue overlying the gluteal muscle, the administering healthcare provider may utilize the supplied 2-inch needle with needle protection device to help ensure that the injectate reaches the intramuscular mass. For very lean patients, the 1 1/2-inch needle may be appropriate to prevent the needle contacting the periosteum. Either needle may be used for patients with average body habitus. Healthcare providers should ensure that the VIVITROL injection is given correctly, and should consider alternate treatment for those patients whose body habitus precludes an intramuscular gluteal injection with one of the provided needles. 

Patients should be informed that any concerning injection site reactions should be brought to the attention of the healthcare provider [see Patient Counseling Information (17)]. Patients exhibiting signs of abscess, cellulitis, necrosis, or extensive swelling should be evaluated by a physician to determine if referral to a surgeon is warranted.
The recommended adult dosage of pantoprazole Sodium for injection is 80 mg intravenously every 12 hours. The frequency of dosing can be adjusted to individual patient needs based on acid output measurements. In those patients who need a higher dosage, 80 mg intravenously every 8 hours is expected to maintain acid output below 10 mEq/h. Daily doses higher than 240 mg or administered for more than 6 days have not been studied [see Clinical Studies (14)] . Transition from oral to intravenous and from intravenous to oral formulations of gastric acid inhibitors should be performed in such a manner to ensure continuity of effect of suppression of acid secretion. Patients with ZE Syndrome may be vulnerable to serious clinical complications of increased acid production even after a short period of loss of effective inhibition.
Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the ?? opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other ?? opioid receptor-mediated conditions.
To improve consistency and usability of X-ray image data.SOLUTION: The present invention relates to a method for automatically adapting an image data set obtained by an X-ray device, a computer program, a data memory, and an X-ray device with corresponding configuration. A method according to the invention relates to individual images (2) of image data set and generates binary masks that differentiate different components (4, 5) of an imaged target object (3) from each other. A reference image of the image data set is determined therefrom, which contains a largest cohesive region (4) of one of the components. From a mean value determined for the region (4) and a specified target value, an offset is determined in such a way that by applying it to the pixel values used for determining the mean value. The pixel values are adapted in such a way that a mean value of the pixel values adapted by the offset corresponds to the specified target value. The determined offset is then applied to all pixel values of the image data set in order to adapt the image data set.SELECTED DRAWING: Figure 6
An extract of the pericarp of Litchi chinensis Sonn. is especially suitable for use in oxidative hair treatment to improve the shine, to improve the texture, and to improve the color retention of hair and to protect the hair from UV radiation. The invention also relates to a method for the oxidative treatment of hair, whereby an oxidative cosmetic agent, which contains an oxidant in a cosmetic carrier, is applied to the hair and is rinsed off the hair after an exposure time. The method is characterized in that directly before the oxidative cosmetic agent is applied, a cosmetic agent, containing an extract of the pericarp of Litchi chinensis Sonn. in a cosmetic carrier is applied and is optionally rinsed off after an exposure time, and/or the oxidative cosmetic agent additionally contains an extract of the pericarp of Litchi chinensis Sonn. The invention allows the above-mentioned properties to be obtained without impairing the result of the oxidative effect of the agent.
A mobile computing device has an image capture device configured to scan a quick response code adhered to a medical linen. Further, the mobile computing device has a processor that generates a graphical user interface having a scanning menu, which lists one or more user selectable indicia. Each of the one or more user selectable indicia is selectable prior to the image capture device performing the scan of the quick response code. Furthermore, each of the one or more selectable indicia is associated with a computer-implemented instruction to update a database via a network. The database stores a data structure corresponding to the medical linen. The one or more selectable indicia are selected from the group consisting of: a medical linen installation indicium and a medical linen disposal indicium.
BACKGROUND: Percutaneous dilatational tracheostomy (PDT) is the preferred method for managing critically ill patients requiring prolonged mechanical ventilation. We aimed to compare the safety of PDT performed by intensivists versus surgeons.
METHODS: This retrospective, single center, cohort study included all the patients who underwent PDT from 2014 to 2023. Propensity score matching was performed to adjust the imbalances of covariates between the groups. The primary outcome was the occurrence of early complications after PDT. Secondary outcomes were the development of late complications of PDT and mortality directly related to tracheostomy.
RESULTS: 1685 consecutive patients with critical illness were included in the analysis. Of these, 1396 (82.8%) PDTs were performed by surgeons and 289 (17.2%) by intensivists with background residency training in internal medicine. Early complications were reported in 80 (5.7%) of the patients in the surgeon group and in 13 (4.5%) patients in the intensivist group (p = 0.40). Minor hemorrhage was the most common early complication. Secondary outcomes were comparable in both groups. In a propensity score-matched cohort, the findings remained consistent.
CONCLUSIONS: This study suggests that PDT can be performed by intensivists, as well as surgeons, with the same safety profile. Our findings underscore the importance of incorporating PDT into the intensive care unit (ICU) training syllabus, ensuring the procedure is readily accessible with reliance on the expertise of ICU staff.
High dose: Participants randomized to the high dose group will receive on day 1 in the clinic an initial dose of 2 mg of buprenorphine/naloxone, followed by a 6 mg dose an hour later, followed by an 8 mg dose an hour later, followed by an 8 mg dose an hour later. On day 2 they will receive a 12 mg dose in the clinic and a 12 mg dose as take-home medication. On days 3 through 7 they will report to the clinic and receive their 12 mg morning dose and a 12 mg dose as a take-home for evening dosing. Thereafter, dosing adjustments can be made in the first three months of the trial.
This group will not receive any exercise intervention but will complete 16 sessions with research staff through videoconferencing. These visits will consist of standardized Health Status Update and education sessions on general health topics.
Physicians from 12 different specialties (i.e. General Medicine, Endocrinologists, Neurologists, Cardiologists, Orthopedists, Pathologists, Rheumatologists, Phytochemists-Pneumonologists, Vascular Surgeons, Oncologists-Pathologists, Psychiatrists, Neurologists-Psychiatrists) who manage patients with non-communicable diseases.
PCT No. PCT/DK85/00005 Sec. 371 Date Oct. 28, 1985 Sec. 102(e) Date Oct. 28, 1985 PCT Filed Feb. 8, 1985 PCT Pub. No. WO85/03436 PCT Pub. Date Aug. 15, 1985.In an oral pharmaceutical controlled release multiple-units formulation, individual units containing an active substance are coated with a substantially water-insoluble, but water-diffusible controlled release coating which includes (1) an inner film layer which causes adhesion between the units at elevated temperatures, comprising a water-dispersible film-forming agent, and (2) an outer film layer comprising a water-based film-forming agent which prevents adhesion between the units at elevated temperatures and imparts flowability to the units. The inner film layer may additionally comprise a substance which is capable of forming a continuous phase. By subjecting the thus coated units to heating to accelerate the formation of a continuous phase of the film-forming agent of the inner layer and optionally also of the additional substance, a coating is formed which substantially does not change its diffusion characteristics in the course of time.
There is growing evidence to suggest that pathophysiology of OSA may lead to atherosclerosis, independent of confounding variables which are often present in these subjects with OSA. Many mechanisms have been reported to contribute to vasculopathy in OSA, but whether increased AGEs formation contribute significantly to the pathogenesis of cardiovascular morbidity in OSA remains to be determined.

Advanced glycation product is formed by non-enzymatic reaction of reducing sugars such as glucose with the amino groups of proteins, and subsequent glycoxidation. AGEs can form on long-lived extracellular proteins as well as short-lived molecules, cytoplasmic proteins and nuclear acids. AGEs cause a number of adverse cellular events and they have been demonstrated in fatty streaks and atherosclerotic plaques. The formation and tissue accumulation of AGE is shown to be enhanced by hyperglycemia and/or increased oxidative stress. There is increasing evidence to support this as an important mechanism of vascular and other end organ damage in diabetes and some other diseases. In OSA, there is evidence to support an increased insulin resistance and excessive oxidative stress, both of which may predispose to AGE formation. We have preliminary data to suggest increased levels of circulating AGE in non-diabetic OSA subjects. Since insulin resistance with elevated blood glucose levels, albeit not up to diabetic thresholds, may partially contribute to increase in AGE.

Many potential mechanisms of atherosclerosis have been reported, but direct evidence for atherosclerosis is still lacking. Subjects with OSA also have comorbidities which may give rise to atherosclerosis. With the advancement of non-invasive techniques for detection of vascular endothelial damage and early atherosclerosis, it is possible to detect early vascular abnormalities in otherwise healthy OSA subjects. This hypothesis underlies our objectives to explore the relationship between AGE and the markers of endothelial dysfunction and early atherosclerosis. Some of these early changes, especially at endothelial level, may be reversible if the insult of OSA is removed. Thus a longitudinal comparison of OSA-treated and OSA-untreated subjects on such changes would further help to clarify the issue.
We will study the antidepressant action of R. rosea in patients with MDD. Depression affects more than a billion people world wide, and is now recognized as one of the most disabling medical conditions. It accounts for more than 11% of the total disease burden worldwide, and can result in devastating consequences and functional impairment exceeded only by that of cancer and cardiovascular disease. It results in substantial social, occupational, and personal disability and in increased medical co-morbidity and death by suicide. It is considered to be a multi-systemic disorder characterized by neurotransmitter, neuroendocrine, immunologic, and autonomic, and infectious disturbances. Although the development of antidepressant drug therapy has simplified the treatment of MDD, a substantial segment of the world's population remains untreated for economic, cultural, or personal reasons. As a result, many individuals seek CAM for relief of their symptoms. The identification of effective CAM therapies for MDD is of public health relevance. R. rosea belongs to the family Crassulaceae, and has a long history as a folk remedy for enhancing physical and emotional endurance. Its adaptogen, or preventive, properties have also led to its use in treating cancer, infection, depression, and other nervous system disorders. Several animal and human studies suggest that R. rosea may have antidepressant properties. For specific aim #1, we will ask: Is R. rosea a safe and effective short-term therapy (vs. sertraline and placebo) for patients with MDD?" To answer this question, patients meeting DSM IV criteria for mild to moderate MDD will be enrolled in a 12-week, randomized, double-blind, placebo-controlled, parallel group, dose-escalation study of R. rosea extract 340-1,360 mg daily vs. sertraline 50-200 mg daily. The primary outcome measure will be change over time in the 17-item Hamilton Depression Rating score. We hypothesize that R. rosea will have superior efficacy vs. placebo and comparable efficacy vs. sertraline. For specific aim #2, we will ask: Does R. rosea therapy result in a favorable tolerability and quality of life (QOL) profile vs. sertraline and placebo? To answer this question, we will obtain safety and QOL measures across treatment conditions that include: (i) frequency, duration, and severity of adverse events, (ii) frequency of serious adverse events, (iii) frequency of dosage reduction, (iv) frequency of treatment discontinuation, and (v) QOL and sexual performance measures. We hypothesize that R. rosea will have a superior tolerability profile vs. sertraline, and similar tolerability vs. placebo. We further hypothesize that R. rosea will have superior QOL and sexual performance ratings vs. sertraline and placebo. Results from this study will be used to inform future research hypotheses and to estimate the effect size necessary to power a future, large scale study.
In controlled trials, hallucination was reported by 4% of ZELAPAR-treated patients and 2% in placebo-treated patients. Hallucinations led to drug discontinuation and premature withdrawal from clinical trials in about 1% of ZELAPAR-treated patients, compared to no patient on placebo. 

Postmarketing reports indicate that patients may experience new or worsening mental status and behavioral changes, which may be severe, including psychotic-like behavior during ZELAPAR treatment or after starting or increasing the dose of ZELAPAR. Other drugs prescribed to improve the symptoms of Parkinson’s disease can have similar effects on thinking and behavior. This abnormal thinking and behavior can consist of one or more of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium. 

Patients with a major psychotic disorder should ordinarily not be treated with ZELAPAR because of the risk of exacerbating psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of ZELAPAR [see Drug Interactions (7.8)].
NP swabs from the Adult population \>17 years, were collected prospectively from adults presenting with symptoms of respiratory illness. Frozen following CLSI guidelines to be Tested at a later time point approximately 3 months.
A system, method and apparatus for forming an emulsion array. An exemplary device includes a frame and at least one or more individual microfluidic modules mounted to the frame and each configured to form an emulsion array. In some embodiments, each module may be mounted by a snap-fit attachment. The apparatus may further include the same sealing member coupled to the top side of each module and hermetically sealing each module. Another exemplary microfluidic device for forming an emulsion array includes stacked layers bonded together. The stack may include a port layer forming a plurality of ports. Each port may have a top rim portion formed by a protrusion around a central axis of the port. The rim portions may be coplanar with one another to facilitate bonding of the sealing member to each rim portion.
The study is designed as a single site, randomized, quadruple-masked, placebo-controlled, parallel group clinical trial. The investigators will screen 343 subjects, with an objective to enroll 144 high risk infants with the PAI-1 risk genotype, who are born between January 1 and May 15, will be randomized (July 15th- August 15th) to one of two treatment groups through the viral season (August 15th to March 15th in 3 yearly cohorts. The treatment groups will be either oral isoflavone supplement (at doses similar to that seen in soy formula) or a matching placebo. Screening will occur January through July of each year, with genotyping occurring at the first visit, and assumption of care of individuals with the risk genotype after randomization. There will be a study run in period until the second week of July at which time subjects will be randomized. At randomization, the investigators will assume the care of the children for all wheezing illnesses. The subjects will have either virtual or in person visits for each of the next 6 visits, followed by an in-person visit at the end of treatment. The subjects will also come in for in-person visits at times of viral illnesses. At randomization, end of treatment, viral illness, and end of study the subjects will have nasal swabs and nasosorption carried out. Blood draws will occur at randomization, end of treatment, and the end of study visit. Stool will be collected for microbiome assessment at randomization, the 3rd or 4th month of treatment, the end of treatment, and the end of the study at the end of the observation year. The study will also measure infant pulmonary function using a wearable device to assess expiratory variability overnight. This will be measured at randomization, viral illness, end of treatment, and at the end of the study after the 1 year observation period. The treatment period will run from August to March 15th for each participant, with a 1 year observation period after this. The study will recruit over 3 consecutive years.
Chimeric anti-large human-mouseAn antibody of an Np protein of the allopan virus and application thereof, wherein a light chain variable region of the antibody has a nucleotide sequence of SEQ ID NO. 1 and an amino acid sequence of SEQ ID NO. 2, and a light chain hypervariable region sequence has a nucleotide sequence of SEQ ID NO. 3, a nucleotide sequence of SEQ ID NO. 4 and a nucleotide sequence of SEQ ID NO. 5; the heavy chain variable region has a nucleotide sequence of SEQ ID NO. 6 and an amino acid sequence of SEQ ID NO. 7, and the heavy chain hypervariable region has a nucleotide sequence of SEQ ID NO. 8, SEQ ID NO. 9 and SEQ ID NO. 10. The antibody can specifically bind to the large allophana virus antigen (Np). Preparation of CDs/SiO-based  2  The immunochromatography reagent of the fluorescent nanospheres has the advantages of simplicity, rapidness, high sensitivity, strong specificity and the like, and is suitable for on-site rapid detection.